Table 2 Methodology and budget results of BIAs
From: A systematic review of the budget impact analyses for antitumor drugs of lung cancer
| First author | Model structure | Perspective | Budget time horizon | Treatment strategy | Cost calculation | Data sources | Sensitivity analysis | Research result |
|---|---|---|---|---|---|---|---|---|
| Carlson [31] | Cost calculator | Health plan | 1 year | Erlotinib maintenance VS Erlotinib maintenance available | Direct cost + condition-related cost | RCT; Medicare and Medicaid and Drug price database; published literature | One-way | Erlotinib PMPM increase |
| Farsai [39] | Cost calculator | Hospital | 4 years | Docetaxel VS Pemetrexed | Direct cost | Hospital inpatient database | One-way | Annual budget of Pemetrexed in hospital increase |
| Sumitra [40] | Markov model | CSMBS | 5 years | Gefitinib;Erlotinib;Pemetrexed;Docetaxel | Direct cost + condition-related cost | RCT;NICE Public data | One-way | Cost saving of Gefitinib |
| Preeti [32] | Cost calculator | Private insurance company | 1 year | Erlotinib;Pac + Car;Bev + Pac + Car;Pem + Car;Bev + Pem +Car | Direct cost | Hospital medical records; Medicare database | One-way | Erlotinib PMPM increase |
| Lisa [33] | Cost calculator | Hospital | 1 year | Ram + Doc; Bev + Erl; Docetaxel; Erlotinib; Pemetrexed | Direct cost | Public Data;Electronic medical record data | NR | After ramucirumab adding to hospital formulary annual margin increase |
| Mengyuan [41] | Cost calculator | Medical insurance | 5 years | Gefitinib VS chemotherapy | Direct cost | Tumor registration information; Project survey; Drug Market Trend Report | One-way | Budget savings after gefitinib is included in the medical insurance catalog |
| Sumitra [42] | Cost calculator | Payer | 3 years | Crizotinib VS no crizotinib | Direct cost + condition-related cost | Thailand official database; Hospital database | One-way | Crizotinib PMPM increase |
| Daniel [34] | Monte Carlo model | Payer | 1 year | Different dose control of the same drug | Direct cost | RCT/SEER and Medicare data | One-way | Budget savings for pembrolizumab of personalized dosing |
| Jan [43] | Cost minimization model | Payer | 1 year | Pembrolizumab VS Docetaxel or pemetrexed | Direct cost + condition-related cost | RCT; National official data | One-way | Pembrolizumab 2nd-line treatment cost savings |
| Pedro [44] | NR | Payer | 1 year | Cost-sharing, risk-sharing, payment-by-results, discount | Direct cost | RCT; National official data | NR | Budget impact of pembrolizumab in the first-line decreased through risk-sharing |
| Christopher [35] | Cost calculator | U.S. commercial and Medicare health plans | 3 years | Before and after adoption of Neci + GCis | Direct cost + condition-related cost | RCT; U.S. prescription information and clinical guidelines; Public data | One-way | Neci + GCis annual budget increase |
| Jonathan [36] | Decision model | U.S. commercial health plan | 5 years | Constant Uptake VS Increase in Afatinib Uptake | Direct cost + condition-related cost | Public data; Project survey; Published literature | One-way | Afatinib annual budget increase |
| Xueyan [45] | Cost calculator | Medical insurance | 5 years | Icotinib VS chemotherapy | Direct cost | Published literature; Project survey data | One-way | Icotinib annual medical insurance cost budget savings |
| Jie [46] | Cost calculator | Medical insurance | 3 years | With and without afatinib in the Chinese national reimbursement system | Direct cost | Published literature; Clinical expert opinion | One-way | Afatinib annual medical insurance budget expenditure decreases |